

































Kamakshi V. Gopal, Major Professor 
Kenneth Melnick, Minor Professor 
Miriam A. Henoch, Committee Member and 
Director of Graduate Studies in Audiology 
Jeffery A. Cokely, Chair of the Department of 
Speech and Hearing Sciences 
C. Neal Tate, Dean of the Robert B. Toulouse 
School of Graduate Studies 
THE EFFECTS OF SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS  
ON AUDITORY MEASURES IN WOMEN 
Kelly Anne Briley, B.A. 
Thesis Prepared for the Degree of 
MASTER OF ARTS 
UNIVERSITY OF NORTH TEXAS 
 
May 2002 
Briley, Kelly, Anne. The Effects of Selective Serotonin Reuptake Inhibitors 
(SSRI) on Auditory Measures in Women. Master of Arts (Audiology), May 2002, 86 
pp., 5 tables, 9 figures, 57 references.  
This study examined the relationship between selective serotonin reuptake 
inhibitor (SSRI) medication and auditory measures in clinically depressed women.  
Experimental subjects were tested in both a medicated and unmedicated condition.  
Experimental subjects were compared to a normal control group; additionally intrasubject 
comparison was made within the experimental group. Test measures included: 
audiometry, tympanometry, otoacoustic emissions, uncomfortable loudness level, 
masking level difference, SCAN-A, Synthetic Sentence Identification (SSI), and the low 
predictability section of the Revised Speech in noise (RSPIN). The unmedicated group 
scored significantly less favorably than the control group on the following tests; SCAN-A 
(composite, filtered words, and auditory figure ground), R-SPIN (0MCR condition in 
both the right and left ears).  Additionally, the unmedicated group scored significantly 
less favorably than the medicated group on the SSI (-20MCR condition right ear only) 
and of the R-SPIN (0MCR condition right ear only). Other test measures indicated 
consistent trends but did reach significance.  
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    CHAPTER 1
Introduction 
Individuals suffering from clinically diagnosed depression are prescribed 
selective serotonin re-uptake inhibitors (SSRI) for relief of their symptoms, since 
there is a growing support for the notion that depressed individuals exhibit a 
compromised balance of the brain neurotransmitter serotonin (5-
hydroxytryptamine; 5HT) (Perez, Bel, Celada, Ortiz, Alverez, & Artigas, 1998).    
Neurotransmitters, such as serotonin, are chemical messengers found in the brain 
that permit communication between nerve cells. Serotonin has both excitatory and 
inhibitory effects on neuronal firing in the central and peripheral nervous systems 
(Jacobs & Fornal, 1993; Thompson, Thompson, Garrett, & Britton, 1994; 
Vandermalen 1985).  Serotonin is released from the neuron into the synaptic cleft 
and either stimulates the adjacent neuron(s) or is reabsorbed by the first neuron.  
Serotonin has been reported to have an effect on vertebrate smooth muscles, 
neuronal cell bodies, dendrites, nerve fibers blood platelets, and glandular 
functions (Vandermalen 1985).  Abnormal function of the serotonergic system 
results in a wide range of neurological and psychological disorders such as 
depression, schizophrenia, anxiety disorders and obsessive-compulsive disorder.  
Pharmacological intervention as a means of balancing the actions of serotonergic 
neurotransmission is central to many therapeutic approaches.  SSRIs are 
antidepressants that increase the serotonin available in the synaptic cleft by 
blocking the mechanism responsible for re-uptake.  This allows for increased 
amounts of the neurotransmitter available for transmission to the next neuron, 
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thereby enhancing serotonergic transmission in the brain (Pinel, 1997; 
Vandermalen, 1985).   
Clinical symptoms seen in patients with serotonergic dysfunction include; 
depression, obsessive-compulsive disorder, obesity, migraine, addictive behaviors 
such as alcoholism, impaired speech perception, intolerance to sensory stimuli 
and hyperacusis.  A pilot study conducted by Gopal et al., (2000), detailed the 
auditory sensitivity and processing ability of a depressed subject who also 
suffered from hyperacusis and difficulty understanding speech.  The patient was 
evaluated both in the medicated and unmedicated condition.  SSRI medication 
improved tolerance to loud sounds, and uncomfortable loudness levels were 
higher in the medicated condition improving the dynamic range of hearing.   
Auditory evoked potentials and otoacoustic emission amplitudes were more 
robust in the unmedicated condition, which could be due to lower inhibition.  In 
the medicated condition, SCAN-A (a screening test for auditory disorders) scores 
were within normal limits; however, in the unmedicated condition the subject 
scored in the disordered range.  The authors attribute these findings to a possible 
dysfunction in the auditory system.  Subsequent research by Bishop (2001) and 
Carney (2001) made static group comparisons of three groups of subjects 
including a control group and to experimental groups, one depressed group not 
taking medication, and one depressed group taking an SSRI.  They investigated 
the relationship between standard audiological tests such as pure tone audiometry, 
tympanometry, acoustic reflexes, masking level difference (MLD), temporal 
integration, amplitude resolution, otoacoustic emissions, uncomfortable loudness 
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level (UCL), along with auditory processing tests such as the SCAN-A, SSI 
(synthetic sentence inventory), and R-SPIN test (revised speech in noise).  
Additional test measure included auditory evoked brainstem and late potentials.  
Significant correlations were found for UCL, amplitude resolution, ABR wave V 
amplitude, and SSI. It is notable to mention that these investigations differ from 
this current study in that the experimental group for the medicated and 
unmedicated condition was comprised of two entirely exclusive groups.  The 
author believes that evaluating intra subject variability, that is evaluating the same 
individuals in a medicated versus unmedicated condition, as opposed to a static 
group comparison, would enhance validity.    
  The purpose of the current study was to evaluate the same individuals in 
both conditions; that is, medicated and unmedicated, allowing for intra-subject 
comparison.  In order to keep the groups more homogenous, only female subjects 
were included in the study.  Currently, little research has been done on the 
peripheral and central auditory effects of SSRI medications.  Comprehensive 
auditory evaluation of clinically depressed individuals taking SSRIs would be of 
value in understanding the role of serotonergic dysfunction in auditory 
processing.  Currently, there is no objective diagnostic test available to diagnose 
clinical depression.  Physicians rely on patient’s individual perceptions of how 
they feel.  Developing an objective, noninvasive diagnostic tool to screen for 
depression would be invaluable not only in identifying and treating more 




Goal of the Study                   
The goal of this study was to identify the role of SSRI medication on 
auditory function in subjects diagnosed with clinical depression.  A second 
objective was to compare the results for the SSRI subjects in their unmedicated 
condition to normal control subjects.  The study consisted of two groups: the 
control group and the experimental group. The control group included individuals 
who had never taken an SSRI medication and were not experiencing symptoms of 
clinical depression.  Individuals in the experimental group had to be taking, or 
planning to take one of five SSRI medications: fluoxetine hydrochloride (Prozac), 
sertraline hydrochloride (Zoloft), fluvoxamine (Luvox), citalopram (Celexa), or 
paroxetine (Paxil).  The experimental subjects were tested once  while on 
medication and once off medication. The test battery consisted of case history, 
otoscopy, pure tone testing, Otoacoustic Emissions (OAEs), Masking Level 
Difference (MLD), dynamic range of hearing based on Uncomfortable Loudness 
Level (UCL), and behavioral speech tests such as SCAN-A (a screening test for 
auditory processing in adolescents and adults), SSI (synthetic sentence inventory), 
low predictability subtest from the R-SPIN (revised speech in noise).  This battery 
allowed for examination of auditory ability from the cochlea to the auditory 







The specific aims of the study were: 
1) Is there a difference in any of the test measures while 
experimental subjects were on medication versus off 
medication? 
2) Is there a difference in the test results between the normal 






















Review of the Literature 
Prelude 
This section will begin with a review the pertinent aspects of the 
serotonergic system, its implication in behavioral and physiological processes, 
and treatment of serotonergic dysfunction with serotonin reuptake inhibitors.  
This will be followed by a review of the neurotransmitter’s involvement in the 
auditory system.  Past research has consistently linked decreased serotonergic 
neurotransmission with depression  (Perez et al., 1998 Jacobs & Fornal, 1993; 
Thompson et al., 1994; Vandermalen 1985).  Although limited, mounting research 
points to serotonergic involvement in the central, and peripheral auditory system 
(Martin & Humphrey, 1994; Thompson et al., 1994, Vandermalen, 1985; Gopal et 
al., 2000).  The current chapter serves to strengthen the role of 5-HT in auditory 
perception and processing.   To provide insight as to why and how the selected 
test measures were used, a subsequent review of relevant literature will be 
included.  
A routine audiological test battery; comprised of otoscopy, tympanometry, 
and pure tone testing will serve to assess the basic integrity of the auditory 
system.  Otoacoustic emissions were chosen in light of their documented success 
in evaluation of outer hair cell function.  Also, contralateral masking of OAEs 
allows for an examination of the suppressive characteristics of the medial 
olivocochlear efferent system.  Masking level difference testing is a well 
established means of assessing lower brainstem integrity and has also been 
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implicated in evaluation of auditory processing ability.  Uncomfortable loudness 
level (UCL) testing was selected as part of the test battery in light of earlier 
research associating hyperacusis and impaired serotonin levels.  A compilation of 
speech tests; including a screening test of auditory processing (SCAN-A), 
synthetic sentence identification (SSI) and the revised speech perception in noise 
(R-SPIN) were chosen to assess both brainstem and central functioning of the 
auditory system. 
 Anatomy of the Serotonergic System 
Jacob and Fornal (1993), noted that the organization 5-HT cell bodies and 
axon terminals is a primitive one, inherent to essentially all vertebrates.  Serotonin 
cell bodies are exclusive to discrete neuronal groups localized in the dorsal and 
median raphe regions of the pons and upper brainstem; however, these cells send 
an extensive network of projections rostral and caudal throughout the nervous 
system. (Vandermalen, 1985).  Prior research has shown serotonergic pathways to 
interface with the auditory system (Bishop, 2001; Carney, 2001; Gopal et al., 
2000; Hegerl & Juckel, 1993; Martin & Humphrey, 1994; Thompson et al., 1994).  
Understanding this connection between serotonin and the auditory system could 
provide insight into complaints of hyperacusis and compromised auditory 
processing in depressed patients with otherwise normal hearing.  Animal research 
by Thompson et. al., (1994) revealed evidence of peripheral 5-HT innervation, 
showing serotonergic terminals that originated in the midline raphe regions of the 
brain to terminate in the cochlear nucleus.  Staining patterns revealed the heaviest 
staining to be localized to the midline raphe nuclei and substantia nigra.  Lighter 
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staining of neuronal terminals occurred in the raphe, substantia nigra, pontine 
nuclei, inferior colliculus, vestibular nuclei, and eighth nerve. 
  Further research done by Gil-Loyzaga, Bartolome, & Vincente-Torres, 
(1997) elucidate the presence of serotonin containing fibers in the cochlear 
nucleus, superior olivary complex, lateral lemniscus, and inferior colliculus.  
Central serotonergic fibers course through virtually all major neuronal structures 
and additionally make contact with cerebrospinal fluid (CSF) and the walls of 
blood vessels.  Electrophysiological studies on both animals and humans have 
shown that intensity dependant auditory evoked potentials (AEP) reflect the 
involvement of serotonin in the auditory cortex (Hegerl & Juckel, 1993; Gallinat, 
Bottlender, Juckel, Puchner, Stoltz, Kuss, Mavroglorgou, & Hegerl, 1999; Juckel, 
Hegerl, Molnar, Csepe, & Karmos, 2000).  The presence of serotonergic 
innervation in both the CNS and the periphery leads to the reasonable hypothesis 
that serotonergic systems may modulate central auditory processing as well as 
sensory pathways such as those related to tolerance of loud sounds and light 
(Martin & Humphrey, 1994; Thompson et al., 1994).  Although this study focused 
exclusively on serotonin, and the effects of its dysregulation on the auditory 
system, one must also acknowledge and understand that serotonin is not the only 
neurotransmitter implicated in depression.  Further examination of these 
neurotransmitters provides additional insight into the biogenic processes of 





A Biogenic Monoamine Hypothesis of Depression: 
 The monoamine hypothesis proposes that depressive symptoms result 
from central monoamine dysfunction (Kandel & Schwartz, 1985, p. 720).  There 
are five acknowledged biogenic amine neurotransmitters: norepinephrine 
(noradrenline), serotonin, dopamine, epinephrine (adrenline), and histamine. 
Functional alterations in one or more of the following systems: serotonergic, 
dopaminergic, and noradrenergic, have been implicated in the pathophysiology of 
depression (Charney 1998).  Recent research supports this notion, showing that 
the use of therapeutic medications which function to increase synaptic levels of 
monoamines in the clinically depressed populations is directly correlated to 
improvements in symptoms (Bruder, Stewart, Tenke, McGrath, Leiti, & Quitkin, 
2001; Menkes, Aghajanian, & McCall, 1980; Pinder, 1997).  
Clinical Features of Depression 
 Clinically diagnosed depression is an overwhelming and debilitating 
disorder, which if sufficiently bad enough, can affect normal working and leisure 
life.  Depression can be classified as unipolar, which involves episodes of 
depression, or bipolar, where the individual experiences episodes of depression 
and mania.  Individuals can experience numerous symptoms including thoughts of 
suicide, guilt, hopelessness, difficulty thinking clearly, agitation and difficulty 
remembering (Kandel, 1991, p. 718; Lucas, 1992; Simpson & Davies 
2000;Whisman, Perez, Ramel, 2000).  Currently, there is not an objective test to 
quantify depression.  Physicians depend on descriptors provided by patients when 
making a diagnosis.  The Diagnostic and Statistical Manual of Mental Disorders 
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Fourth Edition (DSM-IV), published by the American Psychiatric Association, 
provides standard criteria to aid qualified mental health care professionals in 
diagnosing mental disorders.  Criteria for diagnosis of a major depressive episode 
(unipolar depression) requires at least one of the following abnormal moods: 1) 
abnormal depressed mood most of the day, nearly every day, for at least 2 weeks, 
2) abnormal loss of interest and pleasure most of the day, nearly every day, for at 
least two weeks, 3) if 18 or younger, abnormal irritable mood, most of the day, 
nearly every day for at least two weeks.  Further, at least five of the following 
symptoms must be present during the same two weeks depressed period: 1) 
abnormal depressed mood as defined in above criteria, 2) abnormal loss of all 
interest and pleasure as defined in above criteria, 3) appetite or weight 
disturbances, either loss or gain, 4) sleep disturbances, either insomnia or 
hypersomnia, 5) activity disturbances, either abnormal agitation or slowing, 6) 
abnormal fatigue or loss of energy, 7) abnormal self-reproach or inappropriate 
guilt, 8) poor concentration or indecisiveness, 9) abnormal morbid thoughts of 
death or suicide.  The above symptoms cannot be due to mood psychosis, physical 
illness, alcohol, medication, recreational drugs, or normal bereavement.  It is 
notable to mention that he two main physicians who referred subjects for this 
study followed DSM-IV criteria for diagnosis of depression.    
 
Depression and Women 
There is general agreement in the literature that the incidence of depression in 
women is disproportionate to the incidence in men, in fact one of the risk factors 
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in the DSM-IV for depression is being female (American Psychiatric Association, 
1994).  Bruder (2001) sited depression as the most critical mental disorder facing 
women today, with approximately seven million American women implicated.  
Women have consistently exhibited increased risk rates for depression than men 
by a ratio of 2:1 (Bruder, 2001).  The American Psychiatric Association (1994) 
report that 12.9% of women between the ages of 15 to 54 will experience a major 
depressive episode during a 12 month period as opposed to only 7.7% of men.  
Consequently, 63% of depressive occurrences in a one year time period are 
accounted for by women.  Researchers have attempted to explain the disparity 
between incidence of depression in men and women.  One explanation could be  
the demands of marriage, educational status, and family obligations increase the 
risks of depression in women.  Other possible explanations include the idea that 
although men and women undergo a proportional number of negative lifetime 
experiences, women respond to these experiences with greater levels of stress.  
Some  individuals respond to therapeutic medications and experience an 
improvement in depressive symptoms.  
 Depression & SSRIs 
 Serotonin, or 5-hydroxytryptamine, is synthesized from tryptophan, a 
common amino acid and essential dietary requirement. The serotonergic system 
has been shown to be associated with a myriad of behavioral processes including; 
eating, aggression, libido, personality, bulimia, obsessive-compulsive disorder, 
manic depression (bi-polar), schizophrenia and alcoholism (Fuller &Wong 1990; 
Lucas 1992).  Physiological processes may include; motor activity, muscle tone, 
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body temperature, regulation of circadian rhythms, pain transmission, hormone 
release, gastrointestinal function and vasoconstriction (Pinder, 1997; Jacobs & 
Fornal 1993; Lucas 1992; Vandermaelen, 1985).  
It seems clear that serotonin and depression have a strong correlation 
given that the majority of 5-HT receptors in the brain are located in regions 
concerned with mood and anxiety (Martin & Humphrey 1994). Depression 
appears to be closely coupled to decreased activity of the serotonin 
neurotransmitter.  The synapse is the principal structure in the process of 
neurotransmission as it provides a connecting link between nerve cells. 
Concentration of neurotransmitters within the synaptic cleft must be closely 
controlled by the neuron for synaptic transmission to be effective. To achieve this 
balance, neurons execute a sophisticated operation of synthesis, packaging, 
release and degradation.  Once released, serotonin affects multiple membrane 
bound receptor sites. Serotonin travels down the neuron and is released from the 
presynaptic cleft into the synaptic cleft; a re-uptake mechanism, then propagates 
transfer of serotonin back into the nerve terminal where it will be re-packaged and 
stored within synaptic vesicles. When the process of serotonin re-uptake is 
impaired, depression may result.   However, if synaptic activity can be effectively 
controlled, behavioral and physiological processes governed by these synaptic 
transmissions could conceivably be regulated if not controlled.  
 To ameliorate depressive symptoms, individuals often choose 
antidepressant therapy. The first generation of antidepressants, monoamine 
oxidase inhibitors and tricyclics, were not selective and allowed for the reuptake 
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of serotonin, norepinephrine and sometimes dopamine.  Second generation 
antidepressants, selective serotonin reuptake inhibitors (SSRIs), inhibit the 
serotonin uptake carrier with high specificity, enhancing only serotonergic 
activity.  SSRIs also lack the characteristic side effects of their predecessors, 
including anticholinergic (such as adverse muscular effects) and cardiovascular 
effects as well as weight gain (Fuller & Wong 1990).  Fluoxetine (Prozac) is 
likely one of the most widely recognized SSRI and was the first drug of its kind to 
be prescribed in the United States. (Fuller & Wong, 1990, Lucas 1992).  
An objective measurement of serotonin that is not distressing to the patient 
would be a valuable tool in appraising individual effectiveness of SSRI 
medications.  Serotonin concentrations can be measured centrally in cerebrospinal 
fluid (CSF) this method is not clinically feasible due to the invasive method 
required to obtain a valid sample.  Although still a matter of debate in the 
literature, 5-HT can be found peripherally in the blood, intracellularly (platelets) 
and extracellularly (plasma) (Perez 1998).   These two pools are affected 
differently by certain drugs.  Perez (1998) concluded that depressed subjects had a 
significantly lower concentration of 5-HT in plasma as compared with non-
depressed counterparts.  Interestingly, Bongioanni & Selvaggi (1991) found 
subjects displayed a dramatic increase in plasma 5-HT levels following SSRI 
treatment.  Although there has been limited research on the prognostic 
significance of these measures, this inverse relationship between pre-treatment 
and post-treatment 5-HT concentrations in blood could be an indicator of the 
actions serotonergic antidepressant drugs exert on the human serotonin system.  
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Further examination of the connection between blood 5-HT levels and clinical 
improvement could benefit in health care providers in the search for 
individualized treatments for depression. 
Currently the therapeutic success of SSRI medications is established 
through subjective evaluation of patient reported symptom improvement.  
Research by Rappaport, Coccaro, Sheline, Holland, Fabre, & Bradford, 1996, 
revealed consistent improvement in depressive symptoms of patients taking 
Prozac (fluoxetine) as compared to patients who were administered a placebo.  
This lends support to the theory that SSRI medications increase the quantity of 
usable endogenous serotonin in the synaptic cleft.  Of course to fully comprehend 
the relationship between depression, serotonin, and the auditory processes, one 
must first be aware of the intrinsic network of the auditory system. 
 
The Auditory System 
A fascinating aspect of the auditory system is the presence of a parallel 
and sequential network of nerve fibers that send and receive information.  
Afferent pathways relays neurological information from the cochlea to the 
auditory cortex, the contrasting efferent pathway transmits from the brain to the 
cochlea. 
  Afferent auditory pathways originate in the cochlea.  It is through this 
system that sensory information ascends from the periphery to converge with the 
brain.  Neurons in the cochlear nucleus extend their axons, which converge with 
subsequent nuclei, including the superior olivary complex, lateral lemniscus, and 
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inferior colliculus.  Once the pathway reaches the inferior colliculus, fibers cross 
ipsilaterally and contralaterally projecting toward the medial geniculate body. The 
geniculate axons terminate in the primary auditory cortex (Kandel & Schwartz, 
1985).  
 Recent literature supports the existence of two discrete efferent pathways 
between the superior olivary complex and the cochlea.  The first group synapsing 
with cochlear afferent dendrites which are proximal to the principle sensory 
receptors of the auditory system, the inner hair cells.  The second group, the 
crossed, medial olivocochlear efferent system (MOCS), terminates primarily on 
the outer hair cells which are believed to be the source of active cochlear 
mechanisms (Morlet et al., 1999; Parthasarathy, 2001).  Several studies have 
related contralateral acoustic stimulation with a peripheral inhibition response 
(Aran et al., 2000; Collet et al., 1990; Collet, Veuillet, Moulin, Morlet, Giraud, 
Micheyl, & Chery-Croze, 1994; Graham & Hazell, 1994).  Recording otoacoustic 
emissions with contralateral masking may present a direct means of activating the 
medial olivocochlear efferent system and observing the suppressive activity of 
each cochlea. 
 
Serotonin & the Auditory System 
Serotonin (5-Hydroxytryptamine, 5-HT), an amino acid derivative, is a 
neurotransmitter of the monoamine class.  It can be found in abundance in the 
central and peripheral nervous system.  In vertebrates, a preponderance of 5-HT 
producing neurons project from the raphe nuclei and the reticular formation at the 
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medulla oblongata. Areas indicated as being rich in serotonergic fibers include; 
the inferior colliculus, olivary complex, and cochlear nucleus (Gil-Loyzaga, 
Bartolome, & Vincente-Torres 1997; Thompson et al., 1994).  Gil-Loyzaga and 
colleagues (1997), were the first to discover small peripheral distributions of 
serotonergic fibers in the cat cochlea.  The researchers noted that other 
neurotransmitters such as acetylcholine and dopamine, which are part of the 
olivocochlear lateral efferent system (OLES), followed similar innervation 
patterns.  This finding suggests that serotonin may belong to the OLES.       
Stutzman, McEwan & LeDoux (1998), found serotonin-producing cells also 
interface with the amygdala (an area involved in emotions), and the hypothalamus 
(which influences appetite, libido and sleep).   
Investigating the relationship between auditory and serotonergic pathways 
could bring forth new, noninvasive methods of evaluating serotonin levels in 
depressed individuals.  Hegerl and Jeckel (1993) examined the difference in 
auditory evoked potentials as a function of intensity dependence as a means of 
assessing central serotonin neurotransmission.  Findings revealed N1/P1 
amplitude to be dependent on stimulus intensity, with larger, more robust 
amplitudes reflecting low serotonergic transmission.   
Recently, a comprehensive study by Gopal et al., has been able to link 
central and peripheral serotonergic involvement to auditory factors in a human 
subject. The case study examined the relationship between the auditory and 
serotonergic systems of a clinically depressed subject undergoing SSRI treatment.  
Results indicated a change in ABR (auditory brainstem response) intensity 
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dependant components, otoacoustic emissions, auditory processing skills, and 
dynamic range of hearing.  Similar findings by Bishop (2001) and Carney (2001), 
investigating the interactions between auditory measures in subjects taking SSRI 
medications as compared to unmedicated counterparts and controls support these 
findings   
 
Rationale for Test Procedures used in the Study:   
Otoacoustic emissions (OAEs) 
Otoacoustic emissions (OAEs) are pre-neural, sub audible sounds 
generated at the level of the normal cochlea.  In the healthy cochlea, the stimulus 
is processed by the Organ of Corti and as a result a portion of the sound energy is 
re-emitted through the ossicular chain to the external ear (Kemp, Ryan & Bray 
1990; Parthasarathy 2000).  OAEs are believed to be the product of intrinsic, 
nonlinear mechanical activity within the cochlea and provide objective, 
noninvasive information regarding cochlear function.   
Studies indicate that these emitted responses are generated by the 
stimulus-induced motility of the outer hair cells (OHC). Transient and distortion 
product are the two types of evoked emissions and can be elicited in individuals 
with normal hearing.  Response amplitude diminishes as hearing loss progresses; 
elicitation of OAEs will cease once hearing loss reaches approximately 35dB for 
transient evoked otoacoustic emissions (TOAEs) and 50dB for distortion product 
otoacoustic emissions (DPOAEs).    
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 (TOAEs) are generated within the inner ear by a brief click stimulus.  
Averaging (n=260) is used to eliminate environmental noise that may affect 
amplitude.  OAEs follow the tonotopic arrangement of the cochlea, high 
frequency responses having short latencies and mid and low frequency sounds 
having longer latencies.  
 The location of the OHCs is postsynaptic to the medial efferent neurons; 
consequently OHCs are directly modulated by the medial efferent system, 
specifically the medial olivocochlear bundle (MOCB) which originates in the 
medial nuclei of the superior olivary complex (Micheyl, Carbonnel, & Collet 
1995; Morlet et al 1999). Efferent fibers release a crucial inhibitory 
neurotransmitter called acetylcholine (ACh), which is believed to be modulated 
by serotonin (Duffy 1995; Gil-Loyzaga et al. 1997; Thompson et al. 1994). 
Stimulation of the MOCB can be achieved through direct electrical stimulation or 
via contralateral masking (Morlet, Goforth, Hood, Ferber, Duclaux, & Berlin  
1999).  Contralateral acoustic stimulation results in simultaneous activation of the 
crossed and uncrossed MOC efferent system, which in turn results in bilateral, 
peripheral suppression of the auditory system (Aran, Pajor, Charlet du Sauvage, & 
Erre, 2000; Graham & Hazell 1994).  Research suggests that greater reductions in 
TEOAE amplitude under contralateral stimulation is indicative of a stronger 
medial efferent system (Micheyl et al 1995).  Williams, Brookes, & Prasher 
(1993) researched the effect of contralateral acoustic stimulation following 
vestibular neurectomy and found the inhibitory effect of contralateral acoustic 
stimulation to be lacking postoperatively.  It can be concluded from research that 
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lack of suppressive effects is concurrent with compromised efferent functioning 
(Berlin et al., 1995; Tavartkiladze, Frolenkov & Artamasov 1996; Williams, 
Brookes & Prasher 1994).    Franklin et al., (1992) found OAEs to have high test 
re-test reliability, to have low intrasubject variability and to be highly 
reproducible in individuals over time.   
Given this information, the use of OAEs in this study would be 
advantageous in that changes in test results can be interpreted as indication of 
change due to outside induced processes (change in medication status), indicating 
an altered influence of the MOCB in suppression. 
MASKING LEVEL DIFFERENCE (MLD) 
Masking level difference (MLD) testing evaluates lower brainstem 
involvement.  Release from masking is defined as the improvement in the masked 
threshold sensitivity for a signal that occurs on transition from a homophasic 
listening condition to an antiphasic one (Olsen, Noffsinger, Carhart 1976).  
Homophasic listening involves both the signal and the noise being in phase or out 
of phase with each other.  In the antiphasic condition, either of the two stimuli, 
signal or masker, are out of phase with itself while the other is in phase.  MLDs 
are typically obtained binaurally using a 500Hz pulsed tone in the presence of 
narrow band masking noise.  The masking level difference is the difference in 
decibels between the subject’s threshold recognition of the tone in the 
homophasic and then the antiphasic condition.  Sweetow and Reddell, (1978) 
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found tonal MLDs of children with suspected auditory perceptual difficulties to 
be significantly lower than MLDs of age matched peers.  This research indicates 
MLD testing would be a valuable diagnostic test in central auditory batteries.  
Patients with subcortical disorders, such as Meniere’s disease and 8th nerve 
tumors exhibit significantly small MLDs.   In their comprehensive clinical study, 
Olsen Noffsinger and Carhart (1976) found patients having higher cortical 
involvement had normal MLDs; suggesting that release from masking is a 
phenomenon exclusive of mediation by the auditory cortex 
UNCOMFORTABLE LOUDNESS LEVEL (UCL) 
Uncomfortable loudness level (UCL) testing is one of the methods used in 
measuring hyperacusis, dynamic range is evaluated by analyzing the difference 
between the individual’s threshold and UCL.  Clinical hyperacusis is an 
individual’s marked intolerance to ordinary environmental sound in the presence 
of essentially normal hearing (Brady & Lynn 1994).  Studies have implicated both 
the peripheral and central systems in hyperacusis.  Anari et al 1997, noted there 
was a fundamental difference regarding hyperacusis phenomena in several 
patients with peripheral acoustic trauma, as compared to patients exhibiting 
central pathologies including neurosis and depression.  Brady & Lynn (1994) also 
support the belief that peripheral hyperacusis involves the middle ear system and 
cochlea, existing independently from hyperacusis with central and emotional 
elements.  Phillip & Carr (1998) describe the recruitment, a peripheral abnormal 
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growth of loudness as an afferent phenomenon involving a compromised outer 
hair cell system.  This abnormality regarding loudness function is then twofold, 
consisting of an elevated threshold and narrowed dynamic range.  Marriage & 
Barnes (1995) offer the hypothesis that hyperacusic phenomena can be efferent in 
nature without obvious cochlear components.  Further, they argue that central 5-
HT neural systems exert an inhibitory modulation of central responses to sensory 
input.      
SPEECH STIMULI 
SCAN-A:   
Keith (1996) describes the SCAN-A as a more progressive version of the 
SCAN, a screening test for children ages 3 to 11 years old.  Specifically, the 
SCAN-A is used to describe auditory processing abilities in adolescence and 
adults.  The SCAN-A is comprised of four subtests including: filtered words, 
auditory figure ground, competing words, and competing sentences.  In the 
filtered words subtest, the subject is required to repeat monosyllabic words that 
have been passed through a 500Hz filter.  The auditory figure ground subtest 
evaluates the subject’s ability to understand monosyllabic words in the presence 
of background noise similar to cafeteria babble presented at 0dB signal to noise 
ratio.  The competing words subtest is a dichotic test (signals presented to 
separate ears) requiring the subject to repeat the word that was heard in the right 
ear first (the following task is to identify words heard in the left ear first).  The 
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competing sentences subtest is a directed listening task, the subject is asked to 
ignore the sentence presented in one ear and repeat only the sentence heard in the 
test ear.  
In a preliminary study by Gopal et al (2000), investigating the processing 
abilities of a subject exhibiting withdrawn depression, hyperacusis, difficulty 
understanding speech, lethargy, and hypersensitivity to light, sound and touch 
revealed significant differences in SCAN-A scores when the subject was 
evaluated in the medicated (SSRI) condition versus unmedicated condition; scores 
were found to be normal and in the disordered range, respectively.  Subsequent 
research by Bishop (2001) and Carney (2001) revealed similar findings. 
 
SSI (Synthetic Sentence Identification):   
Synthetic Sentence Identification (SSI), developed by Speaks and Jerger 
(1965), is a closed set procedure that employs sentences that have been modified 
from standard rules of grammar and syntax paired with a competing message (a 
narrative about Davy Crockett).  Sentences are presented in two different 
conditions; presentations where the stimulus (sentence) and the competing 
message are in the same ear are referred to as ipsilateral competing message 
(ICM), presentations where the stimulus and competing message are in opposing 
ears are referred to as contralateral competing message (CCM).  Sentences are 
delivered at three different message to competition ratios with regards to a level 
that usually yields 100% (most comfortable loudness level, or MCL).  ICM 
sentences are presented at 0/0dB and 0/-20dB, while CCM are presented at 0/-
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40dB (Willeford & Burleigh 1994).  Jerger & Jerger (1974) found significant 
differences in scores for the ICM condition and the CCM condition in their study 
of eleven subjects with brainstem lesions.  Results revealed the SSI-ICM to be 
particularly sensitive to brainstem lesion with subjects exhibiting more 
pronounced difficulty on the ICM task than the CCM task. 
 
Revised Speech in Noise (R-SPIN):  
  The R-SPIN is a dichotic test presented with background noise or babble 
serving to mimics an environmental listening situation.  The most difficult 
condition, the 0 MCR, stresses the auditory system and requires the subject to 
make sense of words that are distorted by the competing stimuli.   Research has 
indicated that the R-SPIN is of significant value in assessing central auditory 
processing disorder (Jerger, Oliver, & Pirozzolo, 1990).  The Revised Speech in 
Noise test (R-SPIN) consists of both low and high predictability sentences.  Low 
predictability (LP) holding no semantic clues embedded within the sentence and 
high predictability (HP) holding a controlled number of contextual cues to aid the 
subject in identification of the final word in the sentence.  Due to the more 
difficult nature, only the low predictability portion was administered in the test 
battery.   There are eight forms of the R-SPIN each consisting of 25 LP or 25 HP 
sentences (Bilger, Nuetzel, Rabinowitz, & Rzeczkowski (1994)).   
Beck Depression Inventory-II (BDI-II) 
The Beck Depression inventory is widely recognized as an effective, self-
report tool for assessing the severity of depression.  The original BDI, devised in 
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1961 by Beck, Ward, Mock, and Erbaugh, has since been augmented to produce 
the current BDI-II.  This updated design meets the American Psychiatric 
Association’s Diagnostic criteria for diagnosis depressive disorders.  A diagnostic 
criterion was delineated in the 1994 edition of the Diagnostic and Statistical 
Manual of Mental Disorders-Forth edition (DSM-IV).  Respondents are asked to 
answer questions in regard to “the last two weeks, including today.”  The quick to 
administer BDI-II is scored by adding subject responses for each of 21 symptoms.  
The original inventory evolved from clinical observations of the attitudes and 
physiological symptoms of depressed psychiatric patients as compared to non-
depressed counterparts (Endler, Rutherford, & Denisoff, 1999).  The BDI’s 
internal consistency to cognitive and physiological disorders has been affirmed by 
several studies indicating clinically depressed patients consistently score higher 
than nonclinical controls (Beck et al., 1999; Kilgore, 1999; Steer, Clark, Beck, & 
Ranieri 1998).  
Symptoms are broken down into a four-point scale that ranges from 0 to 3.  
Cutoff scoring of the BDI-II assigns a score of 0-12 to be indicative of minimal 
depression, 13-19 indicating mild depression, 20-28 indicating moderate 
depression and 29-63 indicating severe depression (Whisman, Perez, & Ramel, 
2000).  Beck, Steer, Ball, & Ranieri (1999) identified two main dimensions of 
self-evaluative depression in the BDI-II representing somatic-affective and 
cognitive dimensions.  The somatic portion addresses physiological symptoms 
such as fatigue and energy loss while the affective dimension represents 
symptoms such as crying and irritability.    The cognitive aspect of the test relates 
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to psychological symptoms including pessimism and feelings of worthlessness.  
There is general agreement in the literature that ethnicity and age are not 
statistically significant factors in the BDI-II.  It is notable to mention however, 
that on average, women scores 4 points higher than men (Beck, Steer, Ball, & 
Ranieri, 1999; Endler, Rutherford, & Denisoff, 1999; Killgore, 1999). 
 
           Summary of Review 
 The preceding section detailed the serotonergic system and its role in a 
variety of behavioral and physiological processes that are adversely affected by 
deregulation of this system.   Specifically, the association between 5-HT and 
depression was explored.  A variety of auditory tests measures capable of 
assessing areas of the auditory system that have documented serotonergic 
innervation were also detailed.  The purpose of this study was to determine central 
and peripheral effects of selective serotonin reuptake inhibitors (SSRIs) on 











         CHAPTER 3
Methods 
Subjects 
     The participants in the study belonged to either the control group (normal) or 
the experimental group.  The control group consisted of eleven women ages 21 to 
32, who had never received a diagnosis of clinical depression and had never taken 
an SSRI.  The experimental group comprised of 15 women, all having hearing 
within normal limits, ranging in age from 18 to 58.  Inclusion criteria were 1) 
diagnosis of unipolar depression, by a physician, based on DSM IV criteria; 2) 
prescribed one of the following SSRI medications: fluoxetine hydrochloride 
(Prozac), sertraline hydrochloride (Zoloft), fluvoxamine (Luvox), citalopram 
(Celexa), or paroxetine (Paxil).  Furthermore, the experimental subjects were each 
evaluated twice, once when medicated and then again after voluntarily abstaining 
from medication for at least one month.  The one month time period was chosen 
with regards to the SSRI with the longest half life which is fluoxetine (half life=7 
or 8 days). 
Exclusion criteria were 1) males, 2) the existence of concurrent psychiatric 
conditions or other neurological condition.  The decision to include only women 
in the study was made to eliminate the variability of gender.  Research indicates 
that women exhibit a greater incidence of depression than men (Bruder et al., 
2001) and that women score significantly higher than men by an average of four 
points (Beck et al., 1999; Endler, Rutherford, & Denisoff, 1999).    
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Subjects were recruited for the study by means of campus fliers, campus 
newspaper (NT daily), campus television (NTTV).  Subjects were also recruited 
via the UNT Health Center.  All subjects were paid $100 upon successful 
completion of testing.  Subjects were paid from a grant awarded to Kamakshi 
Gopal, Ph.D., by the Texas Advanced Research Program (TARP).  The University 
of North Texas IRB has approved this study. 
 
Procedures:  
 Total testing time was approximately four hours.  If the patient exhibited 
or expressed fatigue, two separate sessions were used.  Test procedures were 
randomized and broken into the following sets: 1) Case history and Beck 
Depression Inventory II (BDI); an SSRI benefit form for medicated condition 
only, 2) otoscopy, tympanometry and pure tone audiometry, 3) transient evoked 
otoacoustic emissions with and without contralateral masking, 4) auditory 
processing tests including the SCAN-A, SSI and R-SPIN, 5) uncomfortable 
loudness level (UCL) to be used in determination of the subject’s dynamic range 
of hearing 6) masking level difference (MLD). 
 
Instrumentation:   
All testing was performed at the University of North Texas.  Additionally, 
raw data for all test procedures is available in the appendices.  Further detail 






All subjects were given the standard case history form used in the 
University of North Texas Speech and Hearing Center. 
 
Beck Depression Inventory 4th Edition (BDI-VI) 
All subjects were given the Beck Depression Inventory 4th Edition and 
asked to base their answers on general physiological and emotional feelings over 
the last two weeks. 
Otoscopy: 
  Otoscopic examination of the ear, using a Welch & Allyn otoscope, 
preceded all test measures to insure that canals were clear and contraindications 
for the test battery were absent. 
 
 Tympanometry: 
Tympanometry was conducted using the Grayson-Stradler GSI-33 
immitance bridge and classified in accordance with Jerger (1970). 
 
 Pure Tone Audiometry: 
Testing was done in sound treated rooms using calibrated earphones 
(TDH-39P) on one of three calibrated audiometers; the Madsen Orbiter 922, 
Auricle or the Grason-Stadler GSI-10 in sound treated rooms.  Air conduction 
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testing following the classic Carhart & Jerger (1959) method was employed for 
octaves 250 through 8000Hz. 
 
 Otoacoustic Emissions: 
Transient evoked otoacoustic emissions (TEOAEs) with and without 
contralateral masking was obtained using the ILO-96 otodynamic analyzer 
(Otodynamics Ltd).  Each condition was tested twice for both the right and left 
ears.  Stimuli used to evoke subject response was 80 microsecond linear clicks of 
70dBpeSPL.  It is generally acknowledged that it is possible for the stapedial 
reflex to affect the emissions reaching the recording microphone (Berlin et al., 
1995; Graham & Hazel, 1994).  So as a preventative measure to assure the 
integrity of the samples, the stimulus level did not exceed of 70dBpeSPL (Collet, 
Kemp, Veuillet, Duclaux, Moulin, & Morgon, 1990).   260 samples were 
averaged to determine OAE amplitudes for the frequencies 1K, 1.5K, 2K, and 3K.  
In all conditions, data from the two runs was averaged for the frequencies of 1K, 
1.5K and 2KHZ.  In the contralateral masking condition, the masker was set at 
30dBSL in regards to the subject’s threshold for the noise.  OAEs were collected 
separately in each ear.  Suppression of OAEs was calculated as the difference 
between masked TOAE and unmasked TOAE. 
Loudness Levels: 
Uncomfortable loudness levels (UCL) were obtained via recorded speech 
in both ears using one of the three before mentioned audiometers.  Using 
Hawkin’s (1984) scale the subjects indicated their perception of an intensity 
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ascending series of sentences.  The procedure was repeated twice to ensure 
accuracy.  The dynamic range was established by obtaining the difference 
between uncomfortable loudness level and pure tone average. 
 
Masking Level Difference (MLD) 
 MLDs were obtained using the GSI-10 audiometer with TDH-39P 
headphones. Noise was constant at 65dB.   A 500 Hz pulsed tone descended in 
decrements of 5dB until the subject could no longer detect the stimulus.  At this 
point, a one-dB bracketing technique was used to determine threshold. Threshold 
measurements were obtained for S0N0, SπN0, and S0Nπ conditions. 
 
Speech Tests: 
 All tests were completed using calibrated earphones (TDH-39P) on one of 
three calibrated audiometers; the Madsen Orbiter 922, Auricle or the Grason-
Stadler GSI-10 in sound treated rooms.  Each individual test material (CD or tape) 
was calibrated before administering.  
 
SCAN-A 
 The SCAN-A (screening test for auditory processing disorders in 
adolescents and adults) was administered in accordance to Keith’s (1995) 
recommendations.  The constant level for this binaural test was the subject’s most 
comfortable listening level (MCL) for each ear.  Raw score were converted to 




Synthetic Sentence Identification Test (SSI) 
 The SSI is a test comprised of recorded non-sense sentences accompanied 
by a story about Davy Crocket as a masker.  Both ears are assessed at presentation 
levels following one of two formats; ipsilateral competing message (ICM) or 
contralateral competing message (CCM).  The ICM was presented at 0 and –20 
message to competition ratio (MCR); the CCM was presented at –40 MCR.  The 
subject’s ability to identify sentences heard through the story was calculated and 
recorded on the scoring form. 
 
Low Predictability Revised Speech Perception in Noise (R-SPIN) 
 The R-SPIN is a monaural test comprised of 50 sentences selected from 
the low predictability section.  Both ears were assessed at presentations of 0 MCR 
(message-to-competing ratio) and +8 MCR.  Final percentages were immediately 
tallied and recorded on the score sheet. 
 
Reliability: 
 The above detailed tests were chosen for their reliability and sensitivity to 
assess different levels of the auditory system known to posses 5-HT innervation.  
Threshold for pure tone audiometry and MLD was obtained using a standard 
bracketing procedure.  Minimum acceptable OAE repeatability was judged by the 
ILO-96 system to be 85% and above.  All speech tests in the battery are 
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standardized for clinical use.  All procedures recommended for clinical use will 
be followed in this study.     
  
Data Analysis:   
     Statistics Program for Social Sciences (SPSS) software was used to analyze 
data.  Mean and standard deviation was obtained for all test measures from all 
subjects.  To compare the results from the control and experimental groups, 
Independent Samples t-test test was used.  Paired Samples t-test was used to 
compare the scores of experimental subjects between their medicated and 
















        CHAPTER 4 
Results and Discussion 
Results 
     This study examined the relationship between SSRI medication and auditory 
measures in women.  Of specific interest was the question of whether auditory 
function was significantly different between:                
1) Experimental subjects medically diagnosed with depression and 
prescribed with an SSRI as compared to control subjects who had 
no history of depression or antidepressant drug use.  
2) Experimental subjects while on SSRI medication versus off SSRI 
medication for at least four weeks.   
     All subjects underwent the following tests: case history, Beck Depression 
Inventory (BDI), otoscopy, tympanometry, pure tone audiometry, otoacoustic 
emissions with and without contralateral masking, uncomfortable loudness level 
(UCL), masking level difference (MLD), SCAN-A, Synthetic Sentence 
Identification (SSI), and Revised Speech In Noise (R-SPIN, low predictability 
list).   
     The following is a summary of test results from each group of subjects.    
Group means and standard deviation were obtained for all test measures.  Raw 
data for specific test results can be found in the appendices subsequent to this 
section.  Group characteristics of all subjects is illustrated in Table 1.  Raw data 




         
 
 Table 1: Sample Size and Age Information 




Sample Size n=11 n=15 





Beck Depression Inventory-II (BDII) 
 The BDI-II provided an assessment of each subject’s perception of their 
level of depression.  Subject’s self ratings were then compared to cut off scores: 
0-12 implying minimal depression, 13-19 implying moderate depression, and 20-
28 implying severe depression.   As shown in Table 2, the control group fell into 
the minimal depression range.  As for the experimental group: while unmedicated, 
subjects fell in the upper limit of moderate depression, and while medicated, 
subjects fell into the lower limit of moderate depression.  Independent Samples t-
test for the control and medicated group revealed a statistically significant 
difference (p=.000) between the BDI scores.  Additionally, the Independent 
Samples t-test for the control and unmedicated group also yielded statistically 
significant results (p=.000).  Paired Samples t-test between medicated and 
unmedicated groups did not yield statistically significant results (p=.066).  Given 
that the BDI-IV yields ordinal level data, median and semi-interquartile range 
were chosen as the measure of central tendency.   Raw data for the BDI-II can be 






Table 2:  Beck Depression Inventory-VI, group means. 




















Basic Audiological Measures 
 Otoscopy revealed clear, unoccluded canals for all subjects.  
Tympanometry revealed type A tympanograms for all subjects except for one 
control and one experimental subject who presented with type Ad tympanograms 
bilaterally.  It should be noted that both subjects with type Ad tympanograms had 
normal hearing, case history revealed recurrent otitis media with concurrent use of 
pressure equalization tubes, this could account for the presence of monomeric 
membranes.  These results are indicative of essentially normal middle ear 
function.  Pure-tone averages (PTAs) were found to be within normal limits 
(<25dBHL), bilaterally for all subjects.  Table 3 presents a synopsis of the afore 


















Otoscopy Normal for all 
ears 
Normal for all ears Normal for all ears 

























Otoacoustic emissions were obtained in two conditions: with and without 
contralateral masking.  An initial unmasked measure was attained, and then OAEs 
were collected with concurrent contralateral masking.  Specifically of interest was 
the three frequency average (1K, 1.5K, and 2K) for the right and left ears.  The 
decision to include only the above mentioned frequencies was made as a result of 
research suggesting that the efferent system to be more functional at low and mid 
frequencies as opposed to high frequencies (Morlet et al., 1999).     Although no 
significant differences were found, a trend was seen wherein the unmedicated 
group consistently produced more robust OAE amplitudes during unmasked and 
masked conditions, in both the right and left ears as compared to the control 
group. Otoacoustic emission p values can be found in table 4a.  Another 
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observation made in this study was that the right ear OAEs were more robust than 
left ear OAEs, this finding was evident in all groups.   Raw data can be found in 
Appendix C. 
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3 freq. ave. Mean: 12.35 Mean: 12.59 Mean: 13.94 
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left ear masked SD: 4.69 SD: 4.60 SD: 5.94 
 







Right ear Left ear Right ear  Left ear 
A=.135 A=.994 Control Group 
3 freq ave, unmasked B=.055 B=.902 
  
A=.250 A=.463 Control Group 
3 freq ave, masked B=.464 B=.554 
  
Experimental Group 
3 freq ave, unmasked 
  .731 .608 
Experimental Group 
3 freq ave, masked 
  .651 .817 
 
 
Uncomfortable Loudness Levels and Dynamic Range 
 Uncomfortable loudness level and dynamic range (calculated as the 
difference between UCL and PTA) was determined bilaterally for each group.  
Table 5 illustrates the average UCL for all groups.  Figure 1 shows the average 
dynamic range which was figured as the difference between uncomfortable 
loudness level and pure tone average.  The control group produced the widest 
dynamic ranges, followed by the medicated experimental group, the unmedicated 
experimental group had the narrowest dynamic ranges.  Although Independent 
Samples t-test results for the control and unmedicated group did not reach 
significance, it is interesting to note that there is a difference in dynamic range 
between the control and unmedicated group of approximately 4 dB, this finding is 
evident for both ears.  When the experimental group was evaluated in the 
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medicated condition, this gap in dynamic range narrowed.  Uncomfortable 
loudness levels and dynamic range p levels can be found in table 5a.   Figure 1 
depicts these data graphically.  Raw data can be found in Appendix D. 
 



























Table 5a: Uncomfortable Loudness Level and Dynamic Range p Values 







Right ear Left ear Right ear  Left ear 
A=.725 A=.584 Control Group 
UCL B=.539 B=.780 
  
A=.520 A=.564 Control Group 




  .178 .205 
Experimental Group 
Dynamic Range 













Masking Level Difference 
 Masking level difference, or release from masking was determined by 
























right ear left ear
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had a mean release from masking of 10.90dB.  The experimental group, while 
medicated, exhibited a mean release from masking of 7.62dB, while unmedicated, 
mean release from masking was 8.75dB. For the SONO-
 			
10.82dB release from masking was obtained for the control group.  The 
experimental group, while medicated displayed a 10.14dB release and while 
unmedicated, a 11.54dB release.  The group differences were not statistically 
significant.  Independent Samples t-test for the SONO-SNO revealed the 
following; control group (p=  Means and standard deviations for each condition 
can be found in Figure 2, SONO-SONπ is represented as Condition A and SONO-
SπNO is represented as Condition B.  Masking Level Difference p levels are 
located in Table 6.   Raw data is shown in Appendix D.  















A=.060 A=.680 Control Group 
 B=.263 B=.743 
  











Behavioral Speech Tests: 
SCAN-A 
    All groups were evaluated at levels corresponding to the individual’s most 
comfortable loudness level (MCL).  The composite score yields percentile ranks 
for each subject based upon the sum of subtest standard scores.  Mean results and 
































Condition A Condition B
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both groups can be found in figures 3 and 4.  For the composite and each subtest, 
with the exception of the competing sentences portion, the control group 
consistently scores better than the experimental group and the scores of the 
experimental unmedicated group improved with SSRI medication.   Results 
indicated a significant difference between the control and unmedicated group for 
the composite, as well as the filtered words and auditory figure ground subtests.  
Independent Samples t-test analysis of composite scores between the control and 
unmedicated groups yielded differences that were statistically significant 
(p=.028).   Individual subtests were then evaluated using an alpha level of .0125.  
Both the filtered words (p=.002) and auditory figure ground (p=.008) were found 
to be significant for the control and unmedicated group.  Although not significant, 
a trend was observed for the competing words subtest, wherein the unmedicated 
experimental group consistently scored less favorably than the control group and 
the medicated experimental group regularly fell in between.  Paired Samples 
analysis did not reveal statistically significant findings between the medicated and 
unmedicated experimental group.  Figure 3 depicts the composite standard score, 
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Table 7: SCAN-A p Values (A=medicated condition, B=unmedicated condition).  
































.305 .837 .213 .013 .822 
 
         Synthetic Sentence Identification (SSI) 
 To attain test scores for the SSI, all groups were evaluated with a message-
to-competing (MCR) ratio of 0 MCR and –20 MCR, these conditions were 
monotic tasks where both the signal and the noise were presented in the same ear.  
The –40 MCR condition was a dichotic task, with the signal presented 
contralateral to the noise.  All groups scored >98% on the –40 MCR portion of 
the test, and >95% on the 0 MCR portion.  Independent Samples t-test for the 
control and medicated experimental groups reached significance for the 0 MCR 
condition in the left ear. Independent Samples t-test the control and unmedicated 
experimental groups did not reach statistical significance, although, it is 
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interesting to note that the experimental group, while unmedicated scored 
approximately 10 points lower than the control group for the right ear –20 MCR 
task (p=0.056).  However, in the Paired Samples t-test between the medicated 
experimental group and the unmedicated experimental group, the –20 MCR 
condition for the right ear yielded statistically significant differences (p= .027).  
Figure 5a, 5b, and 5c detail these data.  Additionally, SSI p Values can be found 
in Table 8.   Raw data is also presented in Appendix G. 
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Figure 5b:  Mean and standard deviation for –20 MCR SSI. 
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Table 8:  SSI p Values, (A=medicated condition, B=unmedicated condition).  











Left ear Right 
ear 
Left ear Right 
ear 
Left ear 




B=.243 B=.056 B=.056 B=.403 B=.577 B=.164 










Left ear Right 
ear 






.500 .567 .027* .237 .164 .336 
 
 
Low Predictability Sentences of the Revised Speech in Noise (R-SPIN) 
 All groups were evaluated in the right and left ears with 0 MCR and +8 
MCR in the ipsilateral condition.  Independent Samples Test revealed a 
significant difference between the control and experimental unmedicated group 
for the 0 MCR condition in the right ear (p=0.035) as well as in the left ear 
(p=0.036).  Paired Samples statistical analysis of the experimental group indicated 
a statistically significant difference between the medicated and unmedicated  
results (p=0.025), with the unmedicated group showing decreased performance on 
 
 49
the 0 MCR.  Figure 6a and 6b below summarize these results.  R-SPIN p values 
can be found in Table 8 below.  Raw data can be found in Appendix H. 
Figure 6a:  Low Predictability R-SPIN, 0 MCR condition. 
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Table 8:  R-SPIN p Values, (A=medicated comdition, B=unmedicated condition).  







Right ear Left ear Right 
ear 
Left ear 






















Summary of Test Results 
          The data in this study, when considered in its entirety, reveals interesting 
relationships between its constituents.  Of all the tests in the battery, only some of 
the behavioral speech test results showed statistically significant differences 
between the groups. Independent Samples t-test revealed differences between the 
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control and unmedicated group for both the SCAN-A (filtered words, auditory 
figure ground and composite standard score), and the 0 MCR condition of the R-
SPIN for both right and left ears. When experimental subjects were evaluated 
while on medication versus off medication using a Paired Samples t-test, 
statistically significant results were found for the 0 MCR of the R-SPIN in the 
right ear as well as the –20 MCR condition of the SSI, also for the right ear.   As 
results indicated, no significant differences were found for masking level 
difference, otoacoustic emissions with or without contralateral masking, 
uncomfortable loudness level or dynamic range 
Discussion 
The purpose of this study was to explore the effects of selective serotonin 
re-uptake inhibitors on both peripheral and central auditory processing measures 
in women.  The following test procedures were used: masking level difference, 
transient evoked otoacoustic emissions (with and without contralateral masking), 
uncomfortable loudness levels, and behavioral speech tests.  The behavioral 
speech tests: SCAN-A, the low predictability test of the R-SPIN and SSI, were 
used for their known sensitivity to detecting deficiencies in auditory processing in 
the lower brainstem and auditory cortex .  The battery as a whole was chosen in 
light of recent research implicating serotonergic pathways in various auditory 
functions (Gallinat et al., 1999; Hegerl & Juckel, 1993; Martin & Humphrey, 
1994; Thompson et al., 1994; Vandermaelen, 1985; Gopal et al., 2000; Bishop, 
2001; Carney, 2001; and Marriage & Barnes, 1995).  Additionally, the Beck 
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Depression Inventory was used to ascertain each subject’s perception of the 
magnitude of their depression.  
 All tests were administered to each of the two groups.  The control group 
consisted of eleven adult women who had never received a clinical diagnosis of 
depression and had never taken SSRI medications.  The experimental group 
consisted of fifteen adult women who had received a diagnosis of clinical 
depression and were willing to be evaluated twice, once while on SSRI 
medication and then again after voluntarily abstaining from medication.  
 The following section will discuss both significant and noteworthy 
findings from the study.  
 
Otoacoustic Emissions 
 Otoacoustic emissions for the frequencies of 1K, 1.5K, and 2KHz were 
averaged and compared using both an Independent Samples t-test and Paired 
Comparison t-test.  Although not statistically significant, a trend was observed 
between the groups wherein the control group consistently had the lowest mean 
OAE amplitude, the unmedicated group consistently had the highest mean 
amplitude, while the medicated group fell in between.  ). Efferent fibers release a 
crucial inhibitory neurotransmitter called acetylcholine (ACh), which is believed 
to be modulated by serotonin (Duffy 1995; Gil-Loyzaga et al. 1997; Thompson et 
al. 1994).  Efferent fibers release a crucial inhibitory neurotransmitter called 
acetylcholine (ACh), which is believed to be modulated by serotonin, it is 
possible that the more robust emissions in the unmedicated experimental group 
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were indicative of a compromised suppression of the medial olivocochlear 
efferent system. (Duffy 1995; Gil-Loyzaga et al. 1997; Thompson et al. 1994).   
These trends remained stable for both the unmasked and masked conditions and in 
both the right and left ears.   Another observation is that each group demonstrated 
higher OAE amplitude in their right ear compared to their left ear.  These results 
are in agreement with previous studies showing transient otoacoustic emissions to 
have higher amplitude in the right ear than in the left suggesting peripheral 
asymmetries in the auditory system (Khalfa & Collet, 1996, Morlet et al., 1999).   
The topic of auditory asymmetry will be discussed further in the behavioral 
speech tests results section.  
 
Uncomfortable Loudness Levels and Dynamic Range 
 Uncomfortable loudness testing is one way to assess hyperacusis.  
Marriage & Barnes (1985) argue that hyperacusis can be efferent in nature, 
without obvious cochlear involvement, thus separating the phenomena from 
recruitment.  These researchers go on to suggest that 5-HT systems modulate 
central responses to sensory input, particularly, sensitivity to sound.   
Baseline UCL measurements were taken using Hawkins’ (1984) loudness 
assessment.  Dynamic range was then computed as the difference between pure 
tone threshold and UCL.  It was anticipated that the unmedicated experimental 
group would exhibit reduced dynamic range and increased perception of loudness.  
Although results failed to reach a level of significance, findings are worth 
remarking on.  The control group had both higher uncomfortable loudness levels 
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and increased dynamic range as compared to the unmedicated group.  In the case 
of dynamic range, the control group had a wider range, followed by the medicated 
experimental group and finally the unmedicated experimental group showed the 
narrowest range.  If central 5-HT neural systems do in fact exert an inhibitory 
modulation of central responses to sensory input, it stands to reason that 
individuals with serotonergic dysregulation would exhibit lower UCL and more 
narrow dynamic ranges as did the unmedicated experimental group in this study.      
  Again it is the opinion of the author that taken into account the interesting trends 
evidenced, a larger sample could result in significant findings. 
 
Masking Level Difference 
 Masking level difference is the decibel difference between threshold for a 
500 Hz tone in an homophasic condition as compared to individual threshold for a 
500Hz tone in an antiphasic condition.  Release from masking is the phenomena 
that occurs when a just inaudible tone becomes audible again by switching the 
phase of the tone through noise.  Abnormal performance on MLD testing, in the 
normal hearing population has been proven to be consistent with brain stem 
disorders such as 8th nerve tumors and multiple sclerosis indicating MLD to be a 
good assessment of brainstem integrity and function (Olsen et al., 1976).  Given 
that 5-HT cell bodies exist exclusively in the raphe nuclei of the brainstem, and 
extend their terminals to both central and peripheral areas, a reasonable 
assumption is that a diagnostic measure that stresses the brainstem could be 
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impaired in individuals with impaired 5-HT function.  However, in this study, 
statistically significant differences were not seen between groups.  
 
Auditory Processing Tests Using Speech Stimuli 
  
SCAN-A 
     Independent Samples t-test analysis showed a significant difference for the 
composite as well as for the filtered words and auditory figure ground subtests 
between the control and unmedicated groups.  Filtered Word test performance is 
indicative of processing abilities for minimally distorted speech.  The Auditory 
Figure ground subtest evaluates the subject’s ability to discriminate words in the 
presence of background noise.  In all subtests of the SCAN-A, the subject is 
required to determine the full message by filling in the missing pieces of the 
distorted message. 
      The evolving trend of the control group scoring highest, the unmedicated 
group scoring the lowest and the medicated group falling somewhere in between 
is again evident.  These findings are analogous to prior research by Gopal and 
colleagues (2000).  Bishop (2001) uncovered similar trends wherein the control 
group consistently scored more favorably than the medicated and unmedicated 
groups and the medicated group scored more favorably than the unmedicated 
group; these results did not reach significance.  
      In the current study, the remaining subtests in the SCAN-A battery failed to 
reach significance, however, the control group continued to score higher than the 
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unmedicated group.  The Paired Samples t-test failed to reveal any significant 
differences.  Although not statistically significant, the experimental unmedicated 
groups’ performance did improve when medicated as seen in all subtests and the 
composite score. 
 
Synthetic Sentence Identification (SSI) 
    Subjects were evaluated in the right and left ears, 0 and –20 message to 
competition ratio (MCR) was obtained in an ipsilateral condition whereas the –40 
MCR portion of the test was obtained in a contralateral condition.   Jerger & 
Jerger (1974) found the ICM portion of the SSI to be particularly sensitive to 
Brainstem lesion, whereas the CCM task stressed higher levels of the auditory 
cortex.   In this study for the most difficult task, the  –20 MCR ICM condition, in 
the right ear, the control group’s mean score (M=81.81) was approximately ten 
points superior to that of the unmedicated group (M=71.33; p=.056).  The Paired 
Samples t-test showed significant differences for the –20 MCR condition in the 
right ear only (p= .027) meaning that when medicated, the experimental group 
performed significantly better on the most difficult right ear task.   
     Again, given that 5-HT neuronal cell bodies originate in the raphe nuclei of the 
brainstem, it was anticipated that results from tests that stress that area of the 
auditory system would prove to be impaired in individuals with a compromised 
serotonergic system.  
 
Low Predictability subtest of the Revised Speech in Noise (R-SPIN) 
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     This test was administered at a level of 0 MCR and +8 MCR, ipsilateraly to the 
right and left ears of each subject.  Independent Samples t-test revealed a 
significant difference between the scores of the control and unmedicated groups 
for the most difficult condition (0 MCR) of the test in both the right (p=.035) and 
left (p=.036) ears.  These results elaborate on earlier findings by Bishop (2001) 
who found trends in the scores of subjects for both ears, wherein the control group 
scored higher than the unmedicated group and the medicated group.    
         Another finding is that significance was found for the right ear only in the 
Paired Samples t-test.  Recent research by Morand et al., (2001) has shown that 
the MOC system is modulated by the auditory cortex.  It has also been suggested 
by the same researchers that examination of Heschl’s gyrus following flumazenil 
binding revealed a left- right asymmetry in favor of the left auditory cortex 
(Morand et al., 2001).  Taken as a whole, it would be reasonable to expect right 
ear dominance in subjects with functioning MOCS, while subjects with impaired 
MOCS would not exhibit a hemispheric dominance and thus a difference in scores 
between the right and left ears would not occur.  Interestingly, upon comparison 
of the scores for the right and left ears for the most difficult portion (0 MCR) of 
the R-SPIN, the experimental group’s scores improved when medicated.  Bruder 
and colleagues (2001) reported on the possible diagnostic potential of using 
dichotic tests as a predictor of response to SSRI treatment in depressed 
individuals.  In their study of both men and women clinically depressed 
outpatients, they found that unmedicated women who later responded to SSRI 
therapy had a greater right ear advantage for dichotic words, there was no 
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significant difference in right ear advantage for men.  Further research exploring 
right ear advantage on the SCAN may support Bruder’s notion that greater 
activity in the left hemisphere during dichotic listening tasks is related to better 
treatment response to SSRI medication.  In the present study is that the medicated 
test results were significantly better than the unmedicated test results only in the 
right ear.  These results, along with Bruder’s (2001) results suggests that the right 
ear which is dominant in most right handed people is more vulnerable to SSRI 
medication.  Furthermore, it can be hypothesized that with SSRI medication, right 




      
     The aim of this study was to study the effects of selective serotonin re-uptake 
inhibitors on peripheral, lower brainstem, and central auditory processing 
measures in clinically depressed women.  The tests selected for this study 
included basic, clinical audiological tests such as pure tone audiometry and 
tympanometry.  Additionally, tests such as masking level difference, 
uncomfortable loudness level, and otoacoustic emissions with and without 
contralateral masking were chosen because of their established sensitivity to 
peripheral and brainstem processing where serotonin is a suspected modulator.  
Auditory processing tests using speech stimuli such as the SCAN-A (a screening 
test for auditory processing in adolescents and adults), the synthetic sentence 
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identification (SSI), and the low predictability sentence portion of the revised 
speech in noise (R-SPIN), were chosen in light of their established sensitivity to 
brainstem as well as cortical lesions.  Statistical analysis revealed the following 
significant results: 
1)  The unmedicated group scored significantly lower than the control    
group on the SCAN-A composite score, as well as on the filtered 
words, and auditory figure ground subtests. 
3) The unmedicated group scored significantly lower than the control 
group on the 0 MCR condition of the low predictability list of the 
R-SPIN in both the right and left ears. 
4) The unmedicated score was significantly lower than the medicated 
scores on the-20 MCR condition of the SSI test in the right ear. 
5) The unmedicated scores were significantly lower than the 
medicated scores on the 0 MCR condition of the R-SPIN in the 
right ear. 
 
     Although the remaining tests failed to reach significance, there were consistent trends 
in several of the tests, including: 
1) Otoacoustic emissions, wherein the unmedicated group displayed 
more robust unmasked amplitude in both the right and left ears 




2) The remaining behavioral speech tests, where the control group 
repeatedly scored more favorably than the unmedicated 
experimental group.  Additionally, the medicated experimental 
group often scored less favorably than the controls and 
consistently scored more favorably than the unmedicated controls. 
 
     The behavioral speech tests uncovered some particularly interesting findings.  The 
control group consistently achieved greater scores, sometimes this was seen as a trend but 
often reached a significant level.  Additionally, auditory processing capability improved 
in the experimental group while the subjects were undergoing therapeutic treatment with 
SSRI medication.  This perhaps suggests that in the experimental group, response to 
SSRI medications promoted increased serotonergic activity and resulted in an 
improvement in auditory processing abilities for speech. 
 
Clinical Relevance 
     Serotonin and its multitude of physiological implications has been the topic of intense 
research for some time.  However, research relating 5-HT to the auditory system is just 
beginning to scratch the surface.  Findings such as those by Gopal et al., (2000), Bishop 
(2001), Carney (2001), and Bruder, (2001) may contribute to the development of a wide 
range of clinical tests that aid in identification of impairments in auditory processing, 
somato-sensory disturbances, serotonergic related disorders, and even predictors of 
patient response to antidepressant treatment.  Several of the tests in this battery, such as 
the uncomfortable loudness level and behavioral speech tests are quick, noninvasive, 
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easy, cost effective evaluations.  With tools such as these available, a physician could 
hopefully identify and treat more of the depressed population as well as monitor 
individual improvement.  It is the author’s wish that this research will contribute to these 
goals and potentially contribute to a wide body of research that may improve the quality 




     The primary constraint of the current study was group size.  Extending the current 
study could reveal better the role of 5-HT in auditory measures.  Regarding the 
behavioral speech tests, the author recommends the use of more difficult testing material 
to further stress the auditory system   Additionally, more homogonous groups in terms of 


















Appendix A: Descriptive Information. 
 
SUBJECT AGE BDI SSRI DOSAGE 
MG/DAY 
BLOOD 
C1 24 6     161 
C2 31 1     136 
C3 22 8       
C4 21 1     126 
C5 23 0     114 
C6 23       219 
C7 23 0     157 
C8 23 0     448 
C9 32 0     158 
C10 23 0     171 
C11 23 0     156 
E1 (1) 20 REFUSED ZOLOFT 50MG 41 
E2(1) 26 14 ZOLOFT 100MG   
E3(1) 21 27 PROZAC 40MG 37 
E4(1) 21 6 ZOLOFT 50MG   
E5(1) 32 4 ZOLOFT 100MG 4 
E6(1) 27     50MG 24 
E7(1) 29 27 PROZAC 40MG   
E8(1) 29 16 ZOLOFT 25MG   
E9(1) 19 11 PROZAC 20MG 24 
E10(1) 18 15 PROZAC 20MG 54 
E11(1) 23 19 PAXIL 20MG 20 
E12(1) 19 6 PROZAC 10MG 31 
E13(1) 22 5 ZOLOFT 50MG 31 
E14(1) 42 21 ZOLOFT 100MG 7 
E15(1) 23 2 PROZAC 20MG 44 
E1(2)   REFUSED     298 
E2(2)   35     45 
E3(2)   10       
E4(2)   29     45 
E5(2)   20     135 
E6(2)         138 
E7(2)   37       
E8(2)   17       
E9(2)   2     148 
E10(2)   39     125 
E11(2)   18     152 
E12(2)   3     143 
E13(2)   4       
E14(2)   31     5 





























Appendix B:  Pure Tone Average & Tympanograms. 
 
SUBJECT PTA-RE PTA-LE TYMPS   
RE/LE 
C1 3 7 A/A 
C2 7 2 A/A 
C3 8 7 Ad/Ad 
C4 5 2 A/A 
C5 5 2 A/A 
C6 5 5 A/A 
C7 1 3 A/A 
C8 5 5 A/A 
C9 0 0 A/A 
C10 5 3 A/A 
C11 0 3 A/A 
E1(1) 7 5 A/A 
E2(1) 8 7 A/A 
E3(1) 8 10 A/A 
E4(1) 5 7 A/A 
E5(1) 3 0 A/A 
E6(1) 20 20 A/A 
E7(1) 7 5 A/A 
E8(1) 0 5 A/A 
E9(1) 18 20 A/A 
E10(1) 2 2 Ad/Ad 
E11(1) 5 3 A/A 
E12(1) 3 3 A/A 
E13(1) 3 3 A/A 
E14(1) 5 5 A/A 
E15(1) 17 17 A/A 
E1(2) 10 5 A/A 
E2(2) 3 3 A/A 
E3(2) 3 7 A/A 
E4(2) 3 5 A/A 
E5(2) 2 0 A/A 
E6(2) 22 20 A/A 
E7(2) 7 3 A/A 
E8(2) 0 2 A/A 
E9(2) 20 25 A/A 
E10(2) 2 3 Ad/Ad 
E11(2) 7 3 A/A 
E12(2) 5 6 A/A 
E13(2) 3 2 A/A 
E14(2) 5 5 A/A 
E15(2) 16 18 A/A 
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Appendix C:  Otoacoustic Emissions (unmasked and Contralateral masking right ear). 
 
















C1 15.5 22 18 16.5 15 23.5 15 17 
C2 4.5 11 7.5 10 11 11 4.5 9 
C3 21.5 13 1.5 10.5 23 8 2 11 
C4 11.5 14 19.5 8.5 3.5 8.5 17 7.5 
C5 3 9.5 8 12 2.5 9 11 17.5 
C6 10.5 11.5 15 15.5 5.5 10 14.5 16.5 
C7 5.5 8.5 12.5 19.5 8 9 12 17.5 
C8 10 17.5 14 12.5 8.5 15.5 13 12 
C9 15.5 21 15.5 15 15.5 17 15 13 
C10 20 25 15 18 16.5 26 15 16.5 
C11 13.5 10.5 10 8 10.5 10.5 10.5 10 
E1(1) 19.5 25 12.5 2 16 23 14.5 5 
E2(1)         7 4 6 10 
E3(1) 13 19.5 19 16.5 15 19 21.5 17.5 
E4(1) 14.5 19.5 19 20.5 12.5 17 17.5 21.5 
E5(1) 10 19.5 9 19.5 12 17 7 17 
E6(1)                
E7(1) 14 23.5 19.5 16.5 11.5 22 17 14.5 
E8(1) 18 20.5 24.5 29 19 22 26 29.5 
E9(1) 3.5 17.8 18.5 3 6.5 19.5 18.5 3 
E10(1) 5 1.5 12.5 18.5 0 0 5 17.5 
E11(1) 12 23 25 22 17 28 25 20 
E12(1) 11 15.5 13.5 8 7.5 14.5 10 9 
E13(1) 17.5 21.5 21.5 15.5 17 19.5 19 16 
E14(1) 15 13 20 14 16.5 14.5 18.5 14.5 
E15(1) 17 8 9 3 13.5 7.5 6 3.5 
E1(2) 19 15 10.5 2 10 20 8.5 0 
E2(2) 15.5 20 14 11 7 4 6 10 
E3(2) 11 19 18 14.5 11.5 20.5 19.5 15.5 
E4(2) 18.5 19.5 21 23 19 19 21 25.5 
E5(2) 17 22.2 13 22.5 15 19.5 14 21 
E6(2) 5.5 13 3 14 0 6.5 0 12 
E7(2) 14 21.5 20 15.5 13 19 20 13 
E8(2) 11.5 19.5 22.5 29 10 18 21.5 29.5 
E9(2) 3.5 11 15 4 7.5 13 17 5.5 
E10(2) 16.5 13.5 18.5 23.5 0 6 14 20 
E11(2) 16.5 26 26 20 18 26 27 21 
E12(2) 9.5 18.5 13 10.5 5.5 15.5 7.5 10 
E13(2) 19 24 21.5 18 20 23 22 18 
E14(2) 22 17 20.5 18 20 18 20 16.5 
E15(2) 12 12 8 13 11 4 2 6 
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Appendix C:  Otoacoustic Emissions (unmasked and contralateral masking left ear). 
 
















C1 13 21 20 21.5 17 21.5 20 19.5 
C2 15 11 4 18 13.5 11 4 17 
C3 20.5 7 15.5 9.5         
C4 14.5 17.5 11 3.5 18 15 10 5.5 
C5 11 15.5 15 14 11.5 18.5 16.5 13.5 
C6 11 11 4 8.5 9 8.5 5 7 
C7 3.5 8.5 13 14.5 0 1.5 13 13.5 
C8 11 13 9.5 12 8 14.5 8.5 11 
C9 21 10.5 7.5 13 25.5 17.5 10.5 11 
C10 14.5 17 14 12.5 10.5 18 14.5 12 
C11 12.5 10.5 9.5 12.5 13 7.5 9 13 
E1(1) 18 14.5 5 0 19 17 3.5 0 
E2(1) 12 12.5 11 11 10 12.5 10.5 8.5 
E3(1) 10 18 9.5 18 8.5 20 14 17.5 
E4(1) 5.5 12.5 16.5 21.5 10 10.5 17.5 21.5 
E5(1) 12 10.5 13 19.5 11 9 13.5 20 
E6(1)                 
E7(1) 14.5 16.5 11.5 15 12 13.5 13 14 
E8(1) 16.5 20 20.5 24 15 21.5 22 24 
E9(1) 2 15 0 0 10 19 5 3 
E10(1) 9 8 1 20 14 11.5 4.5 20 
E11(1) 11 19 21.5 17.5 4 15 22 18 
E12(1) 5 7 6 6 8 10.5 7.5 5.5 
E13(1) 23.5 31 16 16.5 25 28.5 16.5 16 
E14(1) 9 14.5 14.5 8 7 13 13 8 
E15(1) 19 8 5.5 0 7.5 2.5 1.5 0 
E1(2) 31 26 13.5 6.5 25 23 10 4 
E2(2) 18.5 19 12 12.5 17 17 10.5 13 
E3(2) 10.5 18.5 10 15.5 9 19.5 9 14.5 
E4(2) 11.5 13 17 21.5 9.5 12.5 20 23 
E5(2) 18.5 17 16 21.5 18 16 18.5 21.5 
E6(2) 3.5 3 1.5 6.5 1.5 3.5 1 6 
E7(2) 14.5 16 18 16.5 17 14.5 17.5 16 
E8(2) 16.5 21 21.5 27 19.5 21.5 19.5 27.5 
E9(2) 3 12 1 0 0 9.5 2.5 0 
E10(2) 21 20.5 12.5 28 19 21 12 25.5 
E11(2) 9 21.5 23.5 19.5 12 24 23.5 18.5 
E12(2) 6 9.5 6 6 3.5 9.5 5.5 5 
E13(2) 21.5 24.5 15 15 21.5 23.5 15.5 14 
E14(2) 14 13 16.5 14.5 15 14.5 16 14.5 




























Appendix D:  Uncomfortable Loudness Levels and Dynamic Range. 
 




C1 95 95 92 88 
C2 80 75 73 73 
C3 85 85 77 78 
C4 85 85 80 83 
C5 85 85 80 83 
C6 75 75 70 70 
C7 100 100 99 97 
C8 90 90 85 85 
C9 80 80 80 80 
C10 90 90 85 82 
C11 95 95 95 92 
E1(1) 90 95 83 85 
E2(1) 70 70 62 63 
E3(1) 95 95 87 85 
E4(1) 80 80 75 73 
E5(1) 85 80 82 80 
E6(1) 90 95 70 75 
E7(1) 90 90 83 85 
E8(1) 90 95 90 90 
E9(1) 100 100 82 80 
E10(1) 100 100 98 98 
E11(1) 90 90 85 87 
E12(1) 85 85 82 82 
E13(1) 85 80 82 77 
E14(1) 90 90 85 85 
E15(1) 85 85 68 68 
E1(2) 90 95 80 90 
E2(2) 80 75 77 72 
E3(2) 90 90 87 83 
E4(2) 80 80 77 75 
E5(2) 85 85 83 85 
E6(2) 80 90 58 70 
E7(2) 95 95 88 92 
E8(2) 80 80 80 78 
E9(2) 90 85 70 60 
E10(2) 85 85 83 82 
E11(2) 95 90 88 87 
E12(2) 85 85 80 79 
E13(2) 80 75 77 73 
E14(2) 80 85 75 80 



































C1 16 11 
C2 11 14 
C3 3 1 
C4 11 10 
C5 6 10 
C6 13 9 
C7 22 15 
C8 10 15 
C9 10 12 
C10 10 9 
C11 8 13 
E1(1) 11 15 
E2(1) 10 11 
E3(1) 9 12 
E4(1) 3 1 
E5(1) 10 15 
E6(1) 11 7 
E7(1) 7 10 
E8(1) 3 8 
E9(1) 7 9 
E10(1) 0 5 
E11(1) 0 0 
E12(1) 11 16 
E13(1) 4 10 
E14(1) 5 11 
E15(1) 8 12 
E1(2) 8 14 
E2(2) 7 8 
E3(2) 0 0 
E4(2) 1 2 
E5(2) 12 16 
E6(2) 1 1 
E7(2) 12 14 
E8(2) 9 16 
E9(2) 12 16 
E10(2) 0 0 
E11(2) 10 14 
E12(2) 11 16 
E13(2) 12 16 
E14(2) 10 16 





























Appendix F:  SCAN-A (filtered words, auditory figure ground, competing words, 












C1 13 12 13 12 119 
C2 11 9 10 6 92 
C3 14 9 14 12 117 
C4 13 12 12 12 117 
C5 11 13 13 12 117 
C6 14 13 10 12 117 
C7 13 15 9 12 117 
C8 14 13 13 6 112 
C9 14 12 10 12 115 
C10 12 13 13 12 119 
C11 13 13 14 12 121 
E1(1) 12 9 6 9 92 
E2(1) 7 8 13 12 100 
E3(1) 12 10 10 9 102 
E4(1) 14 13 11 13 121 
E5(1) 15 13 14 12 127 
E6(1) 10 12 11 12 112 
E7(1) 15 13 15 12 129 
E8(1) 13 12 12 12 117 
E9(1) 5 9 10 12 92 
E10(1) 13 12 13 12 119 
E11(1) 13 13 9 9 127 
E12(1) 14 10 13 9 112 
E13(1) 9 6 10 12 94 
E14(1) 10 14 12 13 100 
E15(1) 11 8 11 9 98 
E1(2) 8 4 8 9 79 
E2(2) 11 12 12 12 113 
E3(2) 10 10 12 12 104 
E4(2) 12 8 10 12 104 
E5(2) 10 6 11 9 92 
E6(2) 9 10 10 20 117 
E7(2) 12 13 12 12 117 
E8(2) 7 12 11 12 104 
E9(2) 10 12 6 10 38 
E10(2) 12 10 10 6 96 
E11(2) 11 4 8 12 90 
E12(2) 11 10 14 12 113 
E13(2) 14 10 11 12 113 
E14(2) 13 6 12 12 113 
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Appendix G:  Synthetic Sentence Identification. 
 
SUBJECT SSI RE   
0 MCR 
SSI RE   
-20 MCR 
SSI RE   
-40 MCR 
SSI LE   
0 MCR 
SSI LE   
-20 MCR 
SSI LE   
-40 MCR 
C1 100 60 100 100 80 100 
C2 100 100 100 100 90 100 
C3 100 90 100 100 80 100 
C4 100 100 100 100 90 100 
C5 100 80 100 100 90 100 
C6 100 100 100 100 100 100 
C7 100 70 100 100 90 100 
C8 100 80 100 100 90 100 
C9 100 80 100 100 90 100 
C10 90 60 80 100 100 100 
C11 100 80 100 100 100 100 
E1(1) 100 100 100 90 60 100 
E2(1) 100 100 100 100 100 100 
E3(1) 90 70 100 100 70 100 
E4(1) 100 80 100 100 100 100 
E5(1) 100 70 100 100 70 100 
E6(1) 90 60 100 100 100 90 
E7(1) 100 90 100 100 90 100 
E8(1) 100 80 100 100 100 100 
E9(1) 100 100 100 100 100 100 
E10(1) 100 80 100 80 100 100 
E11(1) 100 80 100 90 70 100 
E12(1) 100 80 100 90 70 100 
E13(1) 100 70 100 100 60 100 
E14(1) 70 100 100 90 100   
E15(1) 100 70 100 90 60 100 
E1(2) 100 70 100 100 90 100 
E2(2) 100 70 100 100 100 100 
E3(2) 80 70 100 100 90 100 
E4(2) 100 70 100 100 90 100 
E5(2) 100 80 100 100 80 100 
E6(2) 90 40 90 60 100 100 
E7(2) 100 90 100 100 90 100 
E8(2) 100 80 100 100 80 100 
E9(2) 100 70 100 100 90 100 
E10(2) 100 60 100 100 90 100 
E11(2) 90 70 100 100 90 100 
E12(2) 100 80 100 100 80 100 
E13(2) 90 80 100 100 90 100 
E14(2) 100 60 100 100 80 100 
































RE       
0 MCR 
R-SPIN 
RE       
+8 MCR 
R-SPIN 





C1 68 80 84 92 
C2 44 92 72 96 
C3 52 92 48 96 
C4 68 72 60 88 
C5 68 92 64 96 
C6 72 92 80 60 
C7 84 92 56 92 
C8 72 92 60 100 
C9 48 92 48 92 
C10 56 88 76 48 
C11 80 76 76 72 
E1(1) 52 91 64 86 
E2(1) 76 80 64 92 
E3(1) 64 88 56 76 
E4(1) 60 80 48 80 
E5(1) 60 88 56 76 
E6(1) 68 80 56 96 
E7(1) 60 100 76 92 
E8(1) 68 76 48 80 
E9(1) 48 92 44 84 
E10(1) 100 100 100 100 
E11(1)         
E12(1) 84 96 76 88 
E13(1)         
E14(1) 52 80 48 76 
E15(1) 84 80 40 92 
E1(2) 48 92 60 84 
E2(2) 64 84 52 79 
E3(2) 56 84 60 88 
E4(2) 52 80 24 72 
E5(2) 52 88 56 72 
E6(2) 60 84 52 92 
E7(2) 48 84 80 92 
E8(2) 68 76 48 80 
E9(2) 48 92 44 84 
E10(2) 52 88 48 92 
E11(2) 56 88 36 76 
E12(2) 44 80 56 72 
E13(2) 44 84 60 92 
E14(2) 64 76 64 80 




























Name:  ____________________  Date:  ____________________ 
Age:  ______________________ Phone: ___________________ 
 
Please answer the following questions as best you can. 
1. Medical diagnosis:  Depression_____  Migraine_____________ 
Other: _____________________________________________ 
2. Name of SSRI medication you are currently taking ( Prozac, Paxil, Luvox,   
Celexa, Zoloft). ______________________________________ 
3. Daily Dosage (mg/day) ________________________________ 
4. How long have you been taking this medication? ____________ 
5. SSRI prescribing physician ______________________________ 
6. List all other medications, including herbal supplements, such as St. John’s 
Wort.  _______________________________________________ 
7. Have you noticed any change in you auditory sensitivity and/or speech 
understanding since taking SSRI medication?  ________________ 
_____________________________________________________ 
8.  It is essential for our research to understand how this medication is affecting 
you.  Please describe how you feel this medication is and/or is not helping you 
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